Navigation Links
Rigel Announces Second Quarter 2013 Financial Results
Date:8/6/2013

vesting period and a lower valuation as compared to options granted in the same period of 2012.

For the six months ended June 30, 2013, Rigel reported a net loss of $48.3 million, or $0.55 per basic and diluted share, compared to a net loss of $47.9 million, or $0.67 per basic and diluted share, for the same period of 2012.

As of June 30, 2013, Rigel had cash, cash equivalents and available for sale securities of $251.6 million, compared to $298.2 million as of December 31, 2012.  Rigel expects to end 2013 with cash and investments in excess of $200.0 million, which is expected to be sufficient to fund operations into 2015. 

"This quarter we expect to announce a decision about our future plans for fostamatanib as well as the results of our Phase 2 study with R343 in allergic asthma," said James M. Gower, chairman and chief executive officer of Rigel.  "We also expect to report Phase 2 data with R333 in discoid lupus later in the fall."

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has six product candidates in clinical development: fostamatinib, an oral SYK inhibitor having shown efficacy in certain advanced clinical trials for immune disorders; R343, an inhaled SYK inhibitor for asthma, R333, a topical JAK/SYK inhibitor for discoid lupus, and R348, a topical JAK/SYK inhibitor for chronic dry eye – all in Phase 2 clinical trials; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.

This press release contains "forwa
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Rigel to Present at BIO CEO & Investor Conference
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
11. Rigel Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... , Dec. 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... pharmacy, is proud to announce Jennifer Hagerman , ... Diplomat, will take office as the president of the ... induction ceremony will take place Feb. 28, 2015, at ... held at the Renaissance Center in Detroit, ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical ... company engaged primarily in the development of brachytherapy ... applications, today announced that it has filed a ... and Drug Administration ("FDA") for marketing clearance for ... 513(f)(2) of the U.S. Food, Drug and Cosmetic ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Sept. 28 Delcath Systems, Inc. (Nasdaq: DCTH ... Blair Emerging Growth Stock Conference on Tuesday, October 5, 2010 ... McDonald, Chief Financial Officer, will provide an overview of the ... at this conference is by invitation only. Delcath will offer ...
... be giving their children more medicine than they ... week at Research Forum during Scientific Assembly, the ... Physicians.  Two studies are raising concern about over-the-counter ... Inaccurate" and "Do Parents in the Emergency Department ...
Cached Medicine Technology:Delcath to Present at the William Blair Emerging Growth Stock Conference 2Warnings Re: Over-the-Counter Medication for Children: Less is More 2
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... over an existing treadmill and allows employees to walk and work simultaneously, ... ... 2008 -- Wouldn,t it be wonderful if there was a product that ... shed excess weight and make them more productive? , , , , ...
... risk, study finds , , TUESDAY, Oct. 21 (HealthDay News) -- ... the first time in a decade, particularly among middle-aged white ... we haven,t had as much focus on in terms of ... males, and there has been a lot of attention to ...
... Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading fully ... People,s Republic of China ("PRC"), announced today ... Co. Ltd.,("Harbin First Bio-Engineering"), received $800,000 in ...
... PLYMOUTH MEETING, Pa., Oct. 21 Genaera,Corporation (Nasdaq: ... NASDAQ that the bid price of the Company,s common ... under NASDAQ,Marketplace Rule 4310(c)(4) for the last 30 consecutive ... as of October 16, 2008 it has,suspended for a ...
... BASKING RIDGE, N.J., Oct. 21 Hooper ... Heritage Labs division was awarded a,contract to manufacture ... Westat, an employee-owned corporation providing research services,to agencies ... foundations, and,state and local governments. This component of ...
... are Effective in,Treating Triple-Negative Beast Cancer, According to ... Oct. 21 Decision Resources, one of the,world,s ... issues, finds that significant market penetration will drive,Genentech/Roche/Chugai,s ... total,sales in the breast cancer drug market in ...
Cached Medicine News:Health News:Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity 2Health News:Suicide Rates Rise Among Baby Boomers 2Health News:Suicide Rates Rise Among Baby Boomers 3Health News:China Sky One Medical, Inc. Receives Tax Refund 2Health News:China Sky One Medical, Inc. Receives Tax Refund 3Health News:Genaera Receives Non-Compliance Notice From NASDAQ 2Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 2Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 3Health News:Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study 4Health News:Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017 2
For the quantitative in vitro determination of Carbamazepine in human serum...
For the quantitative in vitro determination of Phenobarbital in human serum....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with particulate (silica) activator....
Medicine Products: